Hideki Makinoshima is a team leader in the Tsuruoka Metabolomics Laboratory, National Cancer Center, at Tsuruoka in Yamagata, Japan. His research program encompasses using cell lines, mice, zebrafish as well as human clinical samples to understand the molecular mechanism controlling cell growth and the metabolic pathways that generate cell components in cancer cells. His long-term career goal is to become a distinguished scientist in the field of cancer metabolism and to develop a new therapy for cancer patients targeting the metabolic pathway in cancer cells.
He conducted the PhD research under the supervision of Dr. Akira Ishihama in the National Institute of Genetics (NIG), Japan. After he had gotten the PhD at Graduate University for Advanced Studies School of Life Science in 2003, he had joined to the laboratory under the supervision of Dr. Michael S. Glickman at Memorial Sloan Kettering Cancer Center. He studies the pathogenesis of infection through a multidisciplinary approach that includes microbial genetics, biochemistry, molecular biology, lipid biochemistry, and immunology.
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.
Genome biology Apr, 2015 | Pubmed ID: 25887790
Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
The Journal of biological chemistry Jul, 2015 | Pubmed ID: 26023239
Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells.
Frontiers in pharmacology , 2018 | Pubmed ID: 30369878
版权所属 © 2025 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。